|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/08/15 Heron Therapeutics, Inc./DE 10-Q 3/31/15 38:2.1M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 164K
2: EX-10.1 Material Contract HTML 20K
3: EX-10.2 Material Contract HTML 20K
4: EX-10.3 Material Contract HTML 15K
5: EX-10.4 Material Contract HTML 18K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 19K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 19K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
24: R1 Document And Entity Information HTML 39K
19: R2 Condensed Consolidated Balance Sheets (Current HTML 76K
Period Unaudited)
22: R3 Condensed Consolidated Statements of Operations HTML 38K
(Unaudited)
26: R4 Condensed Consolidated Statements of Cash Flows HTML 76K
(Unaudited)
34: R5 Note 1 - Business HTML 31K
20: R6 Note 2 - Basis of Presentation HTML 18K
21: R7 Note 3 - Accounting Policies HTML 37K
18: R8 Note 4 - Convertible Notes to Related Parties HTML 23K
16: R9 Note 5 - Stockholders' Equity HTML 79K
35: R10 Note 6 - Income Taxes HTML 20K
28: R11 Significant Accounting Policies (Policies) HTML 52K
27: R12 Note 3 - Accounting Policies (Tables) HTML 23K
31: R13 Note 5 - Stockholders' Equity (Tables) HTML 64K
32: R14 Note 1 - Business (Details Textual) HTML 24K
30: R15 Note 3 - Accounting Policies - Equity Excluded HTML 25K
From Calculation of Diluted Earnings Per Share
(Details)
33: R16 Note 4 - Convertible Notes to Related Parties HTML 66K
(Details Textual)
23: R17 Note 5 - Stockholders' Equity (Details Textual) HTML 94K
25: R18 Note 5 - Stockholders' Equity - Allocation of the HTML 24K
Recognized Cost (Details)
29: R19 Note 5 - Stockholders' Equity - Option Valuation HTML 26K
Assumptions (Details)
38: R20 Note 5 - Stockholders' Equity - Option Summary HTML 40K
(Details)
37: XML IDEA XML File -- Filing Summary XML 49K
15: EXCEL IDEA Workbook of Financial Reports XLSX 56K
17: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 261K
9: EX-101.INS XBRL Instance -- hrtx-20150331 XML 390K
11: EX-101.CAL XBRL Calculations -- hrtx-20150331_cal XML 53K
12: EX-101.DEF XBRL Definitions -- hrtx-20150331_def XML 382K
13: EX-101.LAB XBRL Labels -- hrtx-20150331_lab XML 358K
14: EX-101.PRE XBRL Presentations -- hrtx-20150331_pre XML 391K
10: EX-101.SCH XBRL Schema -- hrtx-20150331 XSD 65K
36: ZIP XBRL Zipped Folder -- 0001193125-15-179414-xbrl Zip 53K
| EX-32.1 |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Each of the undersigned, in his capacity as Chief Executive Officer and Chief Financial Officer, respectively, of Heron Therapeutics, Inc. (the “Registrant”), hereby certifies, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge that:
| • | the Quarterly Report of the Registrant on Form 10-Q for the quarter ended March 31, 2015 (the “Report”), which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| • | the information contained in the Report fairly presents, in all material respects, the financial condition of the Registrant at the end of such quarter and the results of operations of the Registrant for such quarter. |
Dated: May 8, 2015
| /s/ Barry D. Quart |
| Barry D. Quart, Pharm.D. Chief Executive Officer |
| /s/ Brian G. Drazba |
| Vice President, Finance and Chief Financial Officer (As Principal Financial and Accounting Officer) |
This certification accompanies the Report to which it relates, is not deemed to be filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Heron Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.
| Note: | A signed original of this written statement required by Section 906 has been provided to Heron Therapeutics, Inc. and will be retained by Heron Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/8/15 | 8-K | ||
| For Period end: | 3/31/15 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/12/24 Heron Therapeutics, Inc./DE 10-K 12/31/23 72:10M Donnelley … Solutions/FA 3/29/23 Heron Therapeutics, Inc./DE 10-K 12/31/22 73:12M Donnelley … Solutions/FA 2/28/22 Heron Therapeutics, Inc./DE 10-K 12/31/21 74:12M ActiveDisclosure/FA 2/24/21 Heron Therapeutics, Inc./DE 10-K 12/31/20 74:12M ActiveDisclosure/FA |